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ScienceDirectCytochromes P450 catalyze a broad range of regiospecific,
stereospecific and irreversible steps in the biosynthetic routes
of plant natural metabolites with important applications in
pharmaceutical, cosmetic, fragrance and flavour, or polymer
industries. They are consequently essential drivers for the
engineered bioproduction of such compounds. Two ground-
breaking developments of commercial products driven by the
engineering of P450s are the antimalarial drug precursor
artemisinic acid and blue roses or carnations. Tedious
optimizations were required to generate marketable products.
Hurdles encountered in P450 engineering and their potential
solutions are summarized here. Together with recent technical
developments and novel approaches to metabolic engineering,
the lessons from this pioneering work should considerably
boost exploitation of the amazing P450 toolkit emerging from
accelerated sequencing of plant genomes.
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Introduction
Cytochromes P450 (P450s) constitute the most extensively
studied class of enzymes with more than 69 000 articles
published at the end of 2013 (http://www.ncbi.nlm.nih.
gov/queried 20/12/2013 with ‘P450’ or ‘P-450’) according to
PubMed count. An initial strong interest was fostered by§ This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original
author and source are credited.
www.sciencedirect.com the essential roles of several P450s in mammalian drug
metabolism with wide-ranging implications in medicine
and pharmacology [1]. It now appears that they also form
by far the largest superfamily of enzymes, essentially due to
the expansion of the enzyme family in plants. As of Decem-
ber 2013, the count of annotated plant P450s, not including
allelic variants, is 7512 (David Nelson, personal communi-
cation). It is expected that this number will increase in
parallel with the exponential increase in sequencing infor-
mation resulting from ongoing large-scale plant genome/
transcriptome sequencing efforts (e.g. www.onekp.com).
This rapidly expanding repository of P450 sequences could
hold the key to bioengineering and emerging synthetic
biology, when developed into an amazing functional toolkit.
It has been estimated that plants produce more than
200 000 metabolites as signalling, allelochemicals or
defence compounds, to interact with and adapt to their
environment. These metabolites have the potential to
provide a major source of new drugs and bioactive com-
pounds for cosmetics and biopesticides [2,3]. Cytochromes
P450 catalyze most of the rate-limiting (with turnovers
rates typically in the ten to a few hundreds per minute
range) and completely irreversible reactions in their bio-
synthetic pathways, usually regio-specific and stereospe-
cific oxygenations or oxidations, but also more complex
reactions such as dealkylation, deamination, decarboxyla-
tion, C–C cleavage, ring expansion, ring opening, ring
migration, ring coupling and dehydration [4,5].
Extraction of most bioactive compounds from plants is
achieved  with low yield in a costly, season-dependent
and time consuming manner, and is therefore not sus-
tainable. Moreover, many plants containing pharmaceu-
tically interesting compounds are not cultivable, or are at
risk of extinction in their natural habitat. Chemical
synthesis of complex plant metabolites is excessively
expensive. Metabolic engineering in microbial or plant
hosts offers a more cost-effective alternative for pro-
duction of compounds marketable as ‘natural’ products.
We summarize here recent advances involving a combi-
nation of gene function discovery and complex metabolic
engineering that demonstrate how P450s can be
exploited for drug production or to confer valuable traits
to plants for various applications. We also discuss specific
limitations and pitfalls associated with this class of
enzymes, as well as new trends and technical advances
expected to significantly speed-up P450 exploitation in
biotechnology.Current Opinion in Plant Biology 2014, 19:27–34
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engineering
P450s contribute to the biosynthesis and/or catabolism of
all phytohormones, and of many biopolymer (e.g. lignin,
cutin, suberin, sporopollenin) subunits, pigments,
fragrances, flavours, antioxidants, allelochemicals and
defence compounds, among which are many compounds
of commercial interest. Oxidations are critical steps for
the cross-linking of biopolymers and for the formation of
bioactive compounds, and are most often a prerequisite
for further decorations or modifications essential for
bioactivity. For example, 97% of the 46 000 current
recorded plant terpenoids (one of the major classes of
bioactive compounds: Dictionary of Natural Products
(http://dnp.chemnetbase.com) accessed February, 2014;
DNP 22.2 Taylor & Francis Group) are oxygenated [6,7].
When displaying relaxed substrate specificity, P450s can
also participate to the activation or catabolism of xeno-
biotics, such as industrial pollutants or pesticides [8].
Herbicide detoxifying plant P450s can be exploited as
selectable markers for plant transformation [9], whereas
bacterial or human P450 enzymes have been expressed in
plants for the purpose of bioremediation and the removal
of pollutants, including explosives or pesticides
[10,11,12]. Conversely, suppression of herbicide (nico-
sulfuron) detoxification in corn was recently developed as
a tool for controlling the spread of transgenes [13]. So far,
only a very small part of the huge potential provided by
plant P450s has been exploited. A few examples will be
illustrated below.
Major achievements: from engineered
production of artemisinic acid to flower colour
modification
Numerous P450s are already present in the metabolic
engineering toolbox with 2880 US issued patents related
to the use of P450s (source: www.google.com/patents;
query: ‘cytochrome P450’ + ‘metabolic engineering’), of
which around 25% are associated with plants (query:
‘cytochrome P450’ + ‘metabolic engineering’ + ‘plant’).
Few of those, however, have led to commercial appli-
cations.
The most prominent story in synthetic biology for drug
production was recently reported by Paddon and co-
workers [14]. Artemisinin, a sesquiterpenoid originally
sourced from Artemisia annua, is used in combination
therapy for malaria. A stable supply of inexpensive arte-
misinin is essential in the developing world, where
Malaria is a leading cause for death and disease. The
effort for process development was thus supported by the
Bill & Melinda Gates foundation. It was initially found
that a single P450 expressed in the trichomes of A. annua,
CYP71AV1, catalyzes the three successive oxidations
steps leading from amorpha-4,11-diene to artemisinic
acid [15,16]. CYP71AV1 was thus a prime target for
engineered semisynthetic production of artemisininCurrent Opinion in Plant Biology 2014, 19:27–34 (Figure 1a). Commercially relevant yield (25 g/L) was
achieved in baker’s yeast after multiple steps of optim-
ization [14]. The first steps led to optimized production
of amorphadiene in yeast via expression of the amorpha-
diene synthase from A. annua, but also up regulation and
fine-tuning of all enzymes of the mevalonate pathway and
down regulation of ERG9 (encoding squalene synthase
and involved in biosynthesis of sterols) which competes
with the introduced pathway [17,18]. The next stage
required optimization of electron transfer to CYP71AV1,
via moderate expression of the NADPH dependent P450
oxidoreductase (POR) and introduction of A. annua cyto-
chrome b5, preventing the observed formation of reactive
oxygen and the accumulation of toxic intermediates that
interfered with yeast viability. The third stage utilized
acceleration of the formation and channelling of final
oxidation products by co-expression of an artemisinic
aldehyde dehydrogenase and an alcohol dehydrogenase,
both highly represented in A. annua trichome ESTs
(Figure 1a). Final improvements were obtained via opti-
mized yeast cultivation and extractive fermentation pro-
cesses [14]. This outstanding work provides a thorough
and instructive example of metabolic engineering whose
lessons will undoubtedly help speed up future engineer-
ing attempts. It also reveals that although some oxidation
cascades can be achieved by P450s alone, additional
oxidoreductases can be critical to drive fluxes compatible
with viable pathways.
Long and sustained efforts were also required to bring to
the market flowers with modified colours using CYP75
enzymes [19], which are the only CYP-engineered
plants marketed so far. Anthocyanidins determine the
colour of flowers, which shifts from orange via red to violet
and blue hues with increasing hydroxyl groups on the B-
ring. This hydroxylation pattern is determined by two
P450 enzymes of the CYP75 family: the flavonoid 30-and
30,50-hydroxylase (Figure 1b: CYP75B and CYP75A,
respectively). The corresponding genes were initially
identified in petunia and have subsequently been ident-
ified and isolated from a range of different plants [19].
The top-selling cut-flowers such as rose, carnation or
chrysanthemum never show blue shades in nature due
to a CYP75A deficiency. Whereas plant engineering
towards blue flowers seemed initially straightforward,
complex and often empirical strategies had to be imple-
mented to obtain marketable products. In addition to
overexpression of a CYP75A gene, these strategies
included promoter optimization (e.g. promoter from a
snapdragon chalcone synthase), selection of suitable
genetic background, including silencing of competing
pathways, and choice of most efficient CYP75A gene
(with pansy CYP75A showing highest efficiency owing
to better mRNA stability). Further colour improvements
were achieved via coexpression of a 4-dihydroflavanol
reductase (DFR) with appropriate substrate specificity,
and of the flavone synthase II CYP93B, yet anotherwww.sciencedirect.com
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Cytochrome P450 functions in the engineered artemisinin and anthocyanin pathways. (a) Cytochrome P450-catalyzed reactions in the artemisinin
pathway: hydroxylation of amorpha-4,11-diene to produce artemisinic alcohol (1) is catalyzed by the cytochrome P450 CYP71AV1. Artemisinic alcohol
is then synergistically oxidized (2) by CYP71AV1 and ADH1 (artemisinic alcohol dehydrogenase 1) to produce artemisinic aldehyde, which is also
synergistically converted into artemisinic acid (3) by CYP71AV1 and ALDH1 (artemisinic aldehyde dehydrogenase 1). Optimal CYP71AV1 activity
requires two electron donors POR (P450:oxidoreductase) and Cyt b5 (cytochrome b5). (b) Structure and colour of the main types of flower
anthocyanidins. Members of the CYP75B subfamily are flavonoid 30-hydroxylases (F30H), catalyzing B-ring 30-hydroxylation to produce cyanidin-
derived red/magenta pigments. Members of the CYP75A subfamily are flavonoid 30,50-hydroxylases (F3050H), catalyzing both B-ring 30-hydroxylation
and 50-hydroxylation leading to delphinidin-derived violet/blue pigments. Plants deficient in both CYP75A and CYP75B proteins accumulate
pelargonidin-derived red/orange pigments.flavonoid hydroxylase, leading to a deepening and
increase of the blue colour through formation of co-pig-
ments [19]. Other parameters such as vacuolar pH and
metal ion content required control. Optimal electron
transfer was found to be important in some carnation
varieties, requiring overexpression of cytochrome b5 for
accumulation of the blue pigment delphinidin. This is
most likely related to the previously reported require-
ment of cytochrome b5 for CYP75A, but not for CYP75B
activity in petunia [20]. A similar strategy with further
promoter enhancement recently led to the generation of
violet/blue chrysanthemums [21].
Conversely, efforts for engineering pink flowers from
native blue cultivars via suppression of CYP75B and
CYP75A and overexpression of a heterologous DFR gene
from geranium led to pink torenia flowers [22], whereaswww.sciencedirect.com CYP75A suppression was sufficient to shift cyclamen
flowers to orange-red [23].
Both these success stories illustrate that engineering of
industrially relevant processes or products requires more
than P450 expression in a heterologous organism. Optim-
ization of both metabolic fluxes and electron transfer is
required.
The challenge of electron source and transfer
Oxygen activation by P450s requires two electrons (for an
update on P450 mechanism see [24]), which are provided
in vivo via different donor proteins or short protein
cascades [25]. Those depend on organism and subcellular
compartment. While diversified electron donor systems
have evolved in microorganisms, plant P450 enzymes
normally require a POR as minimal electron donor, andCurrent Opinion in Plant Biology 2014, 19:27–34
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Main natural and engineered sources of electrons exploited for P450-driven reactions. In a natural context, the two electrons required for P450
reactions are most often transferred from an N-terminally membrane-anchored P450:oxidoreductase (POR) (a); natural or artificial soluble P450-POR
proteins fusions (as shown in (d)) can be found or generated. In some instances, a C-terminally membrane anchored cytochrome b5 (Cyt b5) is required
to provide the second electron, Cyt b5 being itself reduced by a cytrochrome b5 reductase (b5R) (b). Recent work demonstrates that it is possible to
use photosystem I (PSI)-derived electrons to reduce P450 enzymes via ferredoxin (Fd) in vitro and in vivo (c). Electrode-driven reduction of soluble
P450 is possible in vitro, especially when fused to a redox partner (d).both P450 and POR co-localize on the membrane of
endoplasmic reticulum (or in a few cases on the plastid
envelope) anchored via their N-terminus (Figure 2a).
Achieving high plant P450 activity in microbial cells
usually requires co-expression of a plant POR [26,27].
However, cytochrome b5 might favour (or even be
required for) reduction of some P450 enzymes
(Figure 2b) [14,19,28]. Excess expression of POR is
toxic for the cells since it leads to electron transfer
uncoupling and the generation of chemically generated
reactive oxygen species (see e.g. [14,29]). Probably for
this reason, P450s are usually found in large excess to
POR in plant or animal cells. Optimization of electron
flux to P450s is thus an important aspect of process
development. Some microorganisms have solved this
problem by evolving highly catalytically efficient soluble
P450-POR fusion proteins, the most famous example of
which is P450BM3 from Bacillus megaterium. Artificial
P450-POR fusions were generated with some success
in Escherichia coli where POR and ER membranes are
absent. For example the CYP725A4 from Pacific yew,Current Opinion in Plant Biology 2014, 19:27–34 which catalyses the first oxidation step in the biosynthesis
of the anticancer compound paclitaxel, was found to be
active in E. coli as a fusion with yew POR [30]. Likewise,
plant P450s have been fused to the bacterial POR domain
from Rhodoccocus, generating active enzymes [31]. How-
ever, the arbitrary linkage and protein interactions in such
artificial constructs is not optimized by evolution, and
could therefore lead to poorly performing enzymes, uncou-
pling of electron transfer and other deleterious cellular
effects. Optimization of electron transfer via directed
saturation mutagenesis of the electron donor interface of
a bacterial enzyme has been recently reported [32].
The fact that ferredoxins mediate electron transfer in
mitochondrial and some bacterial P450 systems, and also
function as electron carriers in the photosynthetic chain,
has inspired attempts to replace NADPH by a light-
generated source of electrons in P450 catalyzed biosyn-
thesis of natural products (Figure 2c). Isolated photosys-
tem I membrane complexes in combination with
ferredoxin as an electron carrier were shown to supportwww.sciencedirect.com
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concept of engineering light-driven biosynthesis in syn-
thetic biology [33]. The same team delivered demon-
stration for an entire biosynthetic pathway elegantly in
an in vivo system, effectively rerouting photosynthetic
reducing equivalents into production of a bioactive natural
compound [34]. The key to their strategy was to exploit
the highly compartmentalized nature of plant pathways,
breaking the separation of photosynthetic energy gener-
ation in chloroplasts and P450 based biosynthetic routes
localized to the endoplasmic reticulum. This was achieved
by re-targeting three enzymes to the chloroplast. These
were two P450s and one glycosyl-transferase, constituting
the entire biosynthetic pathway of the plant defence
compound dhurrin, a cyanogenic glucoside found in Sor-
ghum bicolour. It was demonstrated that reduced ferredoxin
generated by photosystem I provided the electrons for the
P450 reactions directly, effectively circumventing involve-
ment of NADPH and the POR [34]. Alternative
approaches aiming at bypassing NADPH dependence
such as coupling of the P450 with photosensitisers to
generate the electrons [35], or non-enzymatic NADPH
regeneration with artificial electron donors and mediators
[36] are in their infancy and have so far only been tested
with the soluble bacterial P450BM3 and complex polypyr-
idin-ruthenium compounds. While interesting from a tech-
nological perspective, the practical and economic
feasibility, and transferability to true production systems
of these technologies remain to be demonstrated.Table 1
Pitfalls, challenges of P450 engineering and possible solutions
Expression level/protein stability and activity
Codon optimization 
Secondary structure optimization 
Decrease expression of POR 
Co-express other POR 
Use other more stable ortholog 
Change expression system 
Expensive co-factors
Whole-cell biotransformation 
Co-factor regenerating system 
Light-driven electron transfer 
Electrode-driven electron transfer 
Toxicity of substrate/intermediates/product
Biphasic bioreactor 
Anion-exchange products trapping 
Conjugation of products 
Compartmentation of products 
Boost flux to final non-toxic products 
Lack of specificity/efficiency/alternative enzyme
Screen natural enzyme collections 
Directed evolution 
Active site design 
Metabolic flux control
Host engineering: expression of upstream/supporting enzymes or silenc
Use of more appropriate natural genetic background 
Co-express optimal protein sets/modular pathway reconstitution/Expres
www.sciencedirect.com Pitfalls of P450-driven metabolic engineering
and potential solutions
P450-mediated metabolic engineering is usually not a
straightforward process. The main challenges and their
possible solutions are summarized in Table 1. The main
limitation for pathway reconstruction in microorganisms
is quite often the level of expression of P450 enzymes.
About 40% of plant P450s are poorly expressed, if at all, in
yeast (from a sample of more than 250 from different
plant species: author’s lab statistics). For enzyme func-
tional characterization, expression in insect cells or plant
tissues can provide alternate strategies, which are not
necessarily relevant for industrial production. Recoding
to match yeast codon usage is not often helpful, although
partial recoding [37] or reducing RNA structure might
provide a more useful approach [38]. A common problem
encountered with heterologously produced bioactive
products is their inherent toxicity when accumulated
as aglycones. In particular, isoprenoid oxygenated pro-
ducts resulting from P450-mediated decoration are
usually more toxic than the corresponding olefins and
exert this toxicity via accumulation in cellular mem-
branes as has been recently shown for nootkatol [39].
In addition, alcohol intermediates may inhibit P450-
catalyzed reactions via direct coordination to the heme
iron in the active site [39]. Plants provide excellent core
metabolism platforms to graft specialized pathways, but
also present a major challenge because of their propen-
sity for further conversion of the desired activatedReferences
[38,41]
[38]
[14]
[26,27,42]
[19,28]
[14,52]
[14,18,39,53]
[36,54,55]
[33,34,56]
[57–59]
[14,41]
[60]
[39,61]
[50,51]
[14,30]
[39,46,47,59]
[62]
[45,63,64]
ing of side-branch pathways [14,17,18,28,30,41,42]
[14,28]
sion level control [14,21,28,30,42,65]
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32 Physiology and metabolismproducts into conjugates or other derivatives due to the
activity of the host plant enzymes (see e.g. [40]). Via
insertion of hydroxyl groups on hydrophobic hydro-
carbon structures, P450s provide grips to oxidoreductases
and conjugations enzymes present in the host organism.
Fast channelling of activated metabolic intermediates to
downstream products is thus required.
New targets and future developments
The main targets for P450-mediated engineered pro-
duction are high-value metabolites with applications in
fragrance/flavour, cosmetics or pharmaceutical industries.
With the development of next generation sequencing,
those are now low-hanging fruits. There are recent reports
of partial reconstruction of pathways for the production of
the diterpenoid taxol [30], triterpenoid ginsenosides [41]
and norditerpenoids tashinones [42], all for pharmaceu-
tical applications. The natural pathways will be exploited,
but the availability of large gene collections also pave the
way for combinatorial assembly of non-natural enzyme
sequences for generation of novel compounds by a syn-
thetic biology approach [43,44], thus expanding the
already huge repertoire of plant metabolites. Moreover,
natural enzyme structures will be redesigned to permit
non-natural reactions as recently elegantly illustrated by
the replacement of the heme axial cysteine ligand with a
serine in the bacterial P450BM3 which generated a C–C
bound forming enzyme catalyzing olefin cyclopropana-
tion [45].
Beside tapping the immense resource for natural
enzymes, major innovations are expected from technical
developments such as novel nanoscale high-throughput
functional screening systems [46,47], enzyme trapping
and stabilization in membrane substitutes such as lipid
nanodiscs [48] or amphipols [49]. The use of new con-
venient plant hosts amenable to homologous recombina-
tion and easily grown in controlled environment, such as
algae or moss, or of specialized plant cell types providing
suitable metabolic backgrounds and allowing product
compartmentation to alleviate toxicity, such as trichomes
[50,51], will open new avenues for plant supported pro-
duction of valuable compounds.
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